BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20169361)

  • 1. Introduction to the special issue of brain structure and function on transgenic modeling of neurodegenerative disorders.
    Hof PR; Elder GA
    Brain Struct Funct; 2010 Mar; 214(2-3):89-90. PubMed ID: 20169361
    [No Abstract]   [Full Text] [Related]  

  • 2. Transgenic zebrafish models of neurodegenerative diseases.
    Sager JJ; Bai Q; Burton EA
    Brain Struct Funct; 2010 Mar; 214(2-3):285-302. PubMed ID: 20162303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transgenic zebrafish as a novel animal model to study tauopathies and other neurodegenerative disorders in vivo.
    Paquet D; Schmid B; Haass C
    Neurodegener Dis; 2010; 7(1-3):99-102. PubMed ID: 20173336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mouse models of neurodegenerative diseases: criteria and general methodology.
    Janus C; Welzl H
    Methods Mol Biol; 2010; 602():323-45. PubMed ID: 20012407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurodegenerative tauopathy in the worm.
    Goedert M
    Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9653-5. PubMed ID: 12913116
    [No Abstract]   [Full Text] [Related]  

  • 6. Conditionally inducible tau mice--designing a better mouse model of neurodegenerative diseases.
    Janus C
    Genes Brain Behav; 2008 Feb; 7 Suppl 1():12-27. PubMed ID: 18184367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Animal models of tauopathies].
    Higuchi M
    Rinsho Shinkeigaku; 2006 Nov; 46(11):928-30. PubMed ID: 17432223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Misfolded tau protein and disease modifying pathways in transgenic rodent models of human tauopathies.
    Zilka N; Korenova M; Novak M
    Acta Neuropathol; 2009 Jul; 118(1):71-86. PubMed ID: 19238406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.
    Williams DR
    Intern Med J; 2006 Oct; 36(10):652-60. PubMed ID: 16958643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation.
    Pérez M; Ribe E; Rubio A; Lim F; Morán MA; Ramos PG; Ferrer I; Isla MT; Avila J
    Neuroscience; 2005; 130(2):339-47. PubMed ID: 15664690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load.
    Koson P; Zilka N; Kovac A; Kovacech B; Korenova M; Filipcik P; Novak M
    Eur J Neurosci; 2008 Jul; 28(2):239-46. PubMed ID: 18702695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transgenic zebrafish model of neurodegeneration.
    Tomasiewicz HG; Flaherty DB; Soria JP; Wood JG
    J Neurosci Res; 2002 Dec; 70(6):734-45. PubMed ID: 12444595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human neurodegenerative disease modeling using Drosophila.
    Bonini NM; Fortini ME
    Annu Rev Neurosci; 2003; 26():627-56. PubMed ID: 12704223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of alpha-tocopherol on an animal model of tauopathies.
    Nakashima H; Ishihara T; Yokota O; Terada S; Trojanowski JQ; Lee VM; Kuroda S
    Free Radic Biol Med; 2004 Jul; 37(2):176-86. PubMed ID: 15203189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anatamopathological spectrum of tauopathies.
    Revesz T; Holton JL
    Mov Disord; 2003 Sep; 18 Suppl 6():S13-20. PubMed ID: 14502651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
    Zhang Q; Zhang X; Sun A
    Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drosophila models of human tauopathies indicate that Tau protein toxicity in vivo is mediated by soluble cytosolic phosphorylated forms of the protein.
    Feuillette S; Miguel L; Frébourg T; Campion D; Lecourtois M
    J Neurochem; 2010 May; 113(4):895-903. PubMed ID: 20193038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repression of tau hyperphosphorylation by chronic endurance exercise in aged transgenic mouse model of tauopathies.
    Leem YH; Lim HJ; Shim SB; Cho JY; Kim BS; Han PL
    J Neurosci Res; 2009 Aug; 87(11):2561-70. PubMed ID: 19360903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neuropathological spectrum of neurodegenerative tauopathies.
    Tolnay M; Probst A
    IUBMB Life; 2003 Jun; 55(6):299-305. PubMed ID: 12938731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.